GlassScriptPhysician profile
Joseph Stephen Ryan
NPI 1588161178
$2,490.77
in general payments reported to CMS, 2019-2025
29 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $244 · 2023: $582 · 2024: $1,124 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.12 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $275.91 | 2021-2025 | Fotivda |
| Amgen INC. | $269.95 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Janssen Biotech, INC. | $222.48 | 2024 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $194.31 | 2021-2024 | Keytruda |
| Sobi, INC | $189.62 | 2023-2024 | |
| Astellas Pharma US INC | $139.01 | 2025 | Xtandi, Padcev |
| Regeneron Healthcare Solutions, INC. | $115.89 | 2022-2024 | Libtayo |
| Kite Pharma, INC. | $93.72 | 2024 | Yescarta |
| Pharmaessentia USA Corporation | $91.82 | 2024 | Besremi |
| Karyopharm Therapeutics INC. | $81.87 | 2022-2023 | Xpovio |
| Genzyme Corporation | $75.43 | 2022-2024 | |
| Eisai INC. | $70.93 | 2024 | |
| Pfizer INC. | $65.74 | 2023 | |
| Glaxosmithkline, LLC. | $64.25 | 2023-2024 | Jemperli, Zejula |
| Array Biopharma INC | $61.18 | 2025 | Braftovi, Lorbrena, Mektovi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $59.76 | 2024 | |
| Seagen INC. | $55.95 | 2021-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $45.99 | 2024 | |
| Genmab U.S., INC. | $43.37 | 2023-2024 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $41.40 | 2021-2024 | Fruzaqla |
| Tersera Therapeutics LLC | $36.46 | 2023 | Zoladex, Xermelo |
| Deciphera Pharmaceuticals INC. | $30.04 | 2023 | Qinlock |
| Biocryst US Sales Co., LLC | $29.21 | 2021 | |
| Cti Biopharma Corp. | $28.23 | 2023 | Vonjo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.51 | 2023 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $23.46 | 2023 | Onivyde, Somatuline Depot |
| Incyte Corporation | $22.81 | 2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $21.47 | 2024 | |
| Daiichi Sankyo INC. | $14.00 | 2023 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.